Hepatitis C and tumors: immune checkpoint inhibitors safe and effective?

被引：0
|
作者：
Simon, Annika
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2024年 / 62卷 / 02期
关键词：
D O I：
10.1055/a-2181-4090
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Wirkstoffe aus der Gruppe der Immun-Checkpoint-Inhibitoren (ICI) haben in den letzten Jahren die Krebstherapie revolutioniert und konnten auch fur Patient*innen mit soliden Tumorerkrankungen und komorbider chronischer Hepatitis-C-Infektion eine neue Therapieoption darstellen. Yibirin et al. wollten daher mehr uber den virologischen Einfluss der ICI und ihre Sicherheit erfahren, und haben eine prospektive Beobachtungsstudie zum Thema durchgefuhrt.
引用
收藏
页码：156 / 158
页数：2
相关论文
共 50 条
  • [31] Increasing cure rates of solid tumors by immune checkpoint inhibitors
    Weijie Ma
    Ruobing Xue
    Zheng Zhu
    Hizra Farrukh
    Wenru Song
    Tianhong Li
    Lei Zheng
    Chong-xian Pan
    Experimental Hematology & Oncology, 12
  • [32] Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors
    Vozy, Aurore
    De Martin, Eleonora
    Johnson, Douglas B.
    Lebrun-Vignes, Benedicte
    Moslehi, Javid J.
    Salem, Joe-Elie
    EUROPEAN JOURNAL OF CANCER, 2019, 123 : 112 - 115
  • [33] Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).
    Cohen, Justine Vanessa
    Misdraji, Joseph
    Dougan, Michael
    Fadden, Riley
    Rubin, Krista M.
    Lawless, Aleigha
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Immune checkpoint inhibitors may be safe for patients with preexisting autoimmune disease
    Fillon, Mike
    CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (01) : 3 - 4
  • [35] Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
    Wang, Mike
    Reynolds, Kerry L.
    Montazeri, Kamaneh
    Schaefer, Esperance A.
    Sullivan, Ryan J.
    Dougan, Michael
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (07) : 1539 - 1541
  • [36] Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
    Shah, Neil J.
    Al-Shbool, Ghassan
    Blackburn, Matthew
    Cook, Michael
    Belouali, Anas
    Liu, Stephen V.
    Madhavan, Subha
    He, Aiwu Ruth
    Atkins, Michael B.
    Gibney, Geoffrey T.
    Kim, Chul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [37] Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
    Ahn, Ryuhjin
    Ursini-Siegel, Josie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 23
  • [38] SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS WITH CHRONIC HEPATITIS C INFECTION: A PROSPECTIVE OBSERVATIONAL STUDY
    Yibirin, Marcel
    Pundhir, Pooja
    Yepez-Guevara, Eduardo
    Granwehr, Bruno
    Kaseb, Ahmed
    Patel, Sapna
    Naing, Aung
    Shah, Amishi Y.
    Skoulidis, Ferdinandos
    Tawbi, Hussein A.
    Zhang, Hao Chi
    Wang, Lan
    Miller, Ethan D.
    Torres, Harrys A.
    HEPATOLOGY, 2020, 72 : 571A - 572A
  • [39] Immune Checkpoint Inhibitors
    Haanen, John B. A. G.
    Robert, Caroline
    IMMUNO-ONCOLOGY, 2015, 42 : 55 - 66
  • [40] Immune checkpoint inhibitors
    Hui, Enfu
    JOURNAL OF CELL BIOLOGY, 2019, 218 (03): : 740 - 741
12345